|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Enhancing the clinical activity of granulocyte- macrophage colonystimulating factor-secreting tumor cell vaccines显示文摘 | Jinushi M Stephen Hodi F Dranoff G | 2008 | Immunol Rev2008，222，： | 1 |
| 2 | Improved survival with ipilimumab in patients with metastatic melanoma显示文摘 | HODI F S O'DAY S J MCDERMOTT D F | | 0，，08： | 1 |
| 3 | Improved sur- vival with ipilimumab in patients with metastatic melanoma显示文摘 | HODI F S O'DAY S J MCDERMOTY D F | 2010 | N Engl J Med2010，363，8： | 1 |
| 4 | Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘 | HODI F S O' DAY S J MCDERMO33' D F | 2010 | N Engl J Med2010，363，8： | 1 |
| 5 | Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating fator by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma 显示文摘 | Soiffer R Hodi FS Haluska F | 2003 | J Clin Oncol2003，21，： | 1 |
| 6 | CTLA-4 and PD-1/PD-L1 blockade : new immunotherapentic modalities with durable clini- cal benefit in melanoma patients 显示文摘 | Ott P A Hodi F S Robert C | 2013 | Clinical Cancer Re- search2013，19，19： | 1 |
| 7 | Pooled analysis of long-term survival data from Phase Ⅱ and Phase III trials of ipilimumab in metastatic or locally advanced,unresectable melanoma 显示文摘 | SCHADENDORF D HODI F ROBERT C | 2013 | Eur J Cancer2013，49，2： | 1 |
| 8 | Safety, activity, andimmune correlates of anti-PD-1 antibody in cancer 显示文摘 | Topalian S L Hodi F S Brahmer J R | 2012 | N EngI J Med2012，366，26： | 1 |
| 9 | Safety, ac- tivity, and immune correlates of anti - PD - 1 antibody in cancer 显示文摘 | TOPALIAN S L HODI F S BRAHMER J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 10 | Survival and long - term follow - up of safety and response in patients (pts) with ad- vanced melanoma (MEL) in a phase I trial of nivolumab ( anti - PD - 1 ; BMS -936558; ONO -4538) 显示文摘 | SZNOL M KLUGER H M HODI F S | 2013 | J Clin Oncol2013，，： | 1 |
| 11 | Improved sur- vival with Ipilimumab in patients with metastatic melanoma 显示文摘 | Hodi F S O'Day S J Mcdermott D F | 2010 | New Engl J Med2010，363，8： | 1 |
| 12 | Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘 | Hodi F S O'Day S J McDermott D F | 2010 | N Enql J Med2010，363，8： | 1 |
| 13 | Safety,activity,and immune correlates of anti-PD-1 antibody in cancer 显示文摘 | TOPALIAN S L HODI F S BRAHMER J R | 2012 | N Engl J Med2012，366，26： | 1 |
| 14 | Biomarkers and associations with the clinical activity of PD - L1 blockade in a MPDL3280A study显示文摘 | POWDERLY J D KOEPPEN H HODI F S | 2013 | J Clin Oncol2013，，： | 1 |
| 15 | Pooled analysis of long- term survival data from phase Ⅱ and phase Ⅲ trials of ipilimumab in un-resectable or metastatic melanoma 显示文摘 | Schadendorf D Hodi F S Robert C | 2015 | J Clin Oncol2015，33，17： | 1 |
| 16 | Improved survival with ipilimumab in patients with metastatic melanoma 显示文摘 | Hodi F S O'Day S J McDermott D F | 2010 | NEnglJMed2010，363，8： | 1 |
| 17 | Multicenter, ran- domized phase II trial of GM - CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 显示文摘 | HODI F S LEE S J MCDERMOTT D F | 2013 | J Clin On- col2013，，： | 1 |
| 18 | Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study 显示文摘 | POWDERLY J KOEPPEN H HODI F | 2013 | J Clin Oncol2013，，： | 1 |
| 19 | Vaccination with irradiated, autologuus melanoma cells engineered to secrete granulocytemac- rophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma显示文摘 | Soiffer R Hodi FS Haluska F et ai | 2003 | J Clin Oncol2003，21，17： | 1 |
| 20 | Therapies-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity 显示文摘 | Jinushi M Hodi F S Dranoff G | 2006 | PNAS2006，103，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员